
    
      The protocol was amended to reflect the change from a phase 2/3 to a study with an expanded
      access program (EAP) in the US that would include patients with ALCL and HL. A later
      amendment allowed patients with CD30-positive cutaneous T-cell lymphoma to enroll. Enrollment
      may continue and patients may receive brentuximab vedotin treatment on study until the drug
      is commercially approved and available to patients in a geographic region.
    
  